Mirati.com

Site Inspections

Overview & More informations

Mirati Therapeutics (MRTX) is a clinical-stage biotechnology company dedicated to developing precision medicines for the treatment of cancer. The company's lead product candidate, MRTX849, is a small molecule inhibitor of KRAS G12C, a mutation found in approximately 13% of all human cancers. Mirati is also developing MRTX1133, a small molecule inhibitor of KRASG12D, which is found in approximately 3% of all human cancers.

The company was founded in 2016 and is headquartered in San Diego, California. Mirati has a team of experienced scientists and executives with a track record of success in the biotechnology industry. The company has raised over $500 million in funding from leading venture capital firms and institutional investors.

Mirati's mission is to develop transformative medicines that improve the lives of patients with cancer. The company's focus on precision medicine allows it to target specific genetic mutations that drive cancer growth. Mirati's lead product candidate, MRTX849, has shown promising results in clinical trials, and the company is currently conducting Phase 3 trials to evaluate the safety and efficacy of the drug in patients with KRAS G12C-mutant non-small cell lung cancer (NSCLC).

If approved by the FDA, MRTX849 would be the first targeted therapy for KRAS G12C-mutant NSCLC. This would represent a major breakthrough in the treatment of this deadly cancer, as there are currently no effective therapies available for patients with this mutation. Mirati is also developing MRTX1133, a small molecule inhibitor of KRASG12D, which is found in approximately 3% of all human cancers. This drug is currently in Phase 1 clinical trials, and Mirati expects to initiate Phase 2 trials in 2023.

Mirati is a promising biotechnology company with a strong pipeline of precision medicines for the treatment of cancer. The company's lead product candidate, MRTX849, has shown promising results in clinical trials, and Mirati is currently conducting Phase 3 trials to evaluate the safety and efficacy of the drug in patients with KRAS G12C-mutant NSCLC. If approved by the FDA, MRTX849 would be the first targeted therapy for KRAS G12C-mutant NSCLC, representing a major breakthrough in the treatment of this deadly cancer.

Domains Expiration Date Updated